These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Reduction in carotid arterial wall thickness using lovastatin and dietary therapy: a randomized controlled clinical trial.
    Author: Hodis HN, Mack WJ, LaBree L, Selzer RH, Liu C, Liu C, Alaupovic P, Kwong-Fu H, Azen SP.
    Journal: Ann Intern Med; 1996 Mar 15; 124(6):548-56. PubMed ID: 8597317.
    Abstract:
    OBJECTIVE: To assess the effects of lipid-lowering therapy on the progression of early, preintrusive carotid arterial atherosclerosis. DESIGN: Randomized, double-blind, placebo-controlled, serial carotid arterial imaging trial. SETTING: University Atherosclerosis Research Unit. PATIENTS: 188 patients from the Monitored Atherosclerosis Regression Study who were 37 to 67 years of age and had angiographically defined coronary artery disease. INTERVENTION: Cholesterol-lowering diet plus placebo or lovastatin, 80 mg/d. MEASUREMENTS: High-resolution B-mode ultrasonographic quantification of the combined thickness of the distal common carotid arterial far wall intima-media complex (carotid arterial intima-media thickness) at baseline and every 6 months for as long as 4 years. RESULTS: The annual rate of change in carotid arterial intima-media thickness differed significantly between the lovastatin group and the placebo group at 2 and 4 years (P < 0.001). CONCLUSION: Lipid-lowering therapy reverses the progression of early, preintrusive atherosclerosis of the carotid artery. Both cholesterol-rich and triglyceride-rich lipoproteins correlate with the progression of early, preintrusive atherosclerosis of the carotid artery. These findings, together with earlier reports of the effects of lovastatin therapy on the progression of atherosclerosis of the coronary arteries, indicate that carotid arterial far wall intima-media thickness is a useful end point for anti-atherosclerosis trials.
    [Abstract] [Full Text] [Related] [New Search]